Health & Bio Desk
Approvals, trials, and the research frontier — where a single regulatory decision reprices a molecule, a company, or a standard of care. This desk reads the health slice of the lattice, from FDA actions to the oncology literature.
$1.6T: annual sales of the global pharmaceutical market — industry estimates.
As of 2026-08-08 · live snapshot.
What the money says
Capital markets read as belief sensors — credit, volatility, and the desk’s own equity basket. Context, not a signal to act on.
The biotech basket (XBI) surged 7.0% this week to $157.37 — the money's view of the domain brightened.
- High-yield credit spread: 2.71% · down 13 bps over 5 sessions · as of 2026-08-06
- 10-year Treasury yield: 4.69% · up 1 bps over 5 sessions · as of 2026-08-06
- Biotech basket (XBI): $157.37 · up 7.0% over 5 sessions · as of 2026-08-07
Public market data, cited as context — not investment advice.
Contracts & awards
From the federal public record (SAM.gov · USAspending): the money actually moving, not the press release about it.
- NIC4 INC — $402K — Drug Enforcement Administration: Department of Justice · USAspending.gov · 2026-08-07
Also tracked on this desk
Subjects whose coverage concentrates in this desk’s domains, counted from the committed corpus — story counts, not estimates.
On the desk wire
Names native to this desk moving across the whole lattice right now. Click through for momentum, coverage, and the read.
FDA
In 10 verticals across 11 domains
Colorectal Cancer
In 3 verticals across 2 domains
Eli Lilly
In 4 verticals across 4 domains
Immunotherapy
In 4 verticals across 2 domains
Moderna
In 4 verticals across 4 domains
BP
In 6 verticals across 6 domains
CMS
2.3x acceleration + migrated from biotech_pharma, construction, fda_decisions +1 more to aging
In the coverage
The desk’s read of what its sources reported most recently. Distilled from 943 fresh items across 338 sources on this desk’s beat — the full lattice feeds every desk; these are the top reads.
- Normal Tissue Dosimetry of Intraperitoneal 224Ra Microparticle Therapy: Data from First-in-Human Studies in Patients with Peritoneal Metastases. · J Nucl Med · 2026-08-06
- Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCO · European Journal of Cancer · 2026-08-02 · syndicated across 2 pickups
- [Articles] Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, rando · The Lancet Oncology · 2026-08-02
- Beyond a Metabolite: Lactylation as a Pivotal Regulator of Colorectal Cancer Pathogenesis and Treatment Resistance. · J Biochem Mol Toxicol · 2026-08-01
- Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Tria · Journal of Clinical Oncology · 2026-07-30 · syndicated across 2 pickups
- Corrigendum to “Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 347 · Annals of Oncology · 2026-07-29
- Neoadjuvant chemotherapy and bevacizumab for colorectal peritoneal metastases: clinical and translational outcomes of the phase II BEV-IP trial. · Transl Oncol · 2026-07-29
- Cell-Free DNA Concentration as a Mutation-Agnostic Readout of Systemic Tumor Burden and Prognosis: A Prospective Analysis of 1,000 Patients · medRxiv Oncology · 2026-07-28
- A phase II multi-center, open-label, randomized, parallel-group, superiority study to compare the acute toxicity of Hypofractionated dOse Painted External radiotherapy ve · medRxiv Oncology · 2026-07-27
- Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase II · Journal of Clinical Oncology · 2026-07-26
- Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial. · Nat Commun · 2026-07-23 · syndicated across 2 pickups
- Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial. · Clin Cancer Res · 2026-07-23
- J&J’s bispecific combo slashes myeloma progression risk by 89% in phase 3 trial · Fierce Pharma · 2026-07-22
- A single-arm phase II trial of UGT1A1 genotype-guided high-dose irinotecan rechallenge in refractory metastatic colorectal cancer. · Front Oncol · 2026-07-22
- First-Line Immunotherapy Versus Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis of Phase III Studies. · J Gastrointest Cancer · 2026-07-20
- OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head a · British Journal of Cancer · 2026-07-18
- Vogenx joins the IPO queue to fund phase 2-stage metabolic drug · Fierce Biotech · 2026-07-16
- Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update · Fierce Biotech · 2026-07-16
- Oncogenic KRAS Promotes Extracellular DNA Clearance to Drive Immunosuppression in Colorectal Cancer. · Cancer Res · 2026-07-15
- Kelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 program · Fierce Pharma · 2026-07-15
- Randomized phase III Study of Adding Paclitaxel to Chemoradiotherapy With Capecitabine and Mitomycin C in Squamous Cell Anal Carcinoma · Clinical Colorectal Cancer · 2026-07-14
- [Articles] Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial · The Lancet Oncology Online First · 2026-07-14
- AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/ · Clinical Colorectal Cancer · 2026-07-12
- First-In-Human [177Lu]Lu-FAPI-XT Therapy Combined With Anti–PD-1 Antibody in a Patient With Metastatic Colon Cancer Who Has Progressed on Multiple Prior Lines of Therapy · JCO Precision Oncology · 2026-07-11
Questions the desk is watching
What this desk sees, in your inbox: the record, the moves, and the read, written for managers whose portfolio is the world.
Informational only — not investment advice. Market-size figures are editorial estimates with sources as noted; contract and award lines are drawn from public federal records via our tracked pipelines.